FDA Approves Supplemental New Drug Application for Veltassa Removing Boxed Warning Regarding Drug-Drug Interactions
November 28, 2016 01:00 ET
|
Relypsa, Inc.
The updated label recommends patients take Veltassa at least 3 hours before or after other oral medications; previously the label recommended a 6-hour separation timeData from the drug-drug...
Relypsa Announces Data on the Treatment and Impact of Hyperkalemia to be Presented at ASN Kidney Week 2016
November 03, 2016 16:30 ET
|
Relypsa, Inc.
REDWOOD CITY, Calif., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc., a Vifor Pharma Company, today announced five posters, including new analyses from studies of Veltassa® (patiromer) for oral...
Relypsa Announces Phase 4 Study Shows Veltassa® Demonstrated Similar Efficacy and Safety Whether Given With or Without Food in Patients with Hyperkalemia
August 30, 2016 16:05 ET
|
Relypsa, Inc.
REDWOOD CITY, Calif., Aug. 30, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced that the Phase 4 TOURMALINE study, which compared the efficacy and...
Galenica and Relypsa Announce Agreement for Galenica to Acquire Relypsa
July 21, 2016 01:00 ET
|
Relypsa, Inc.; Galenica Group
– Acquisition Strengthens Galenica’s Business Unit, Vifor Pharma – Galenica will commence a tender offer to acquire all issued and outstanding Relypsa common stock for a cash consideration of...
Relypsa Announces New Employment Inducement Grants
July 18, 2016 16:15 ET
|
Relypsa, Inc.
REDWOOD CITY, Calif., July 18, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on July 5, 2016, the compensation committee of the company’s...
Relypsa to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference
July 06, 2016 08:30 ET
|
Relypsa, Inc.
REDWOOD CITY, Calif., July 06, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP) today announced that John A. Orwin, president and chief executive officer, will present at the Cantor Fitzgerald...
Results of Pre-Specified Exploratory Analysis of Phase 3 OPAL-HK Study Evaluating Effects of Veltassa on Blood Pressure and Aldosterone Published in Kidney International
June 27, 2016 16:16 ET
|
Relypsa, Inc.
REDWOOD CITY, Calif., June 27, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced that results of a pre-specified exploratory analysis of the Phase 3...
Relypsa Announces New Employment Inducement Grants
June 17, 2016 16:10 ET
|
Relypsa, Inc.
REDWOOD CITY, Calif., June 17, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on June 15, 2016, the compensation committee of the company’s...
Relypsa Announces New Employment Inducement Grants
June 06, 2016 16:15 ET
|
Relypsa, Inc.
REDWOOD CITY, Calif., June 06, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on June 1, 2016, the compensation committee of the company’s...
Relypsa Submits Supplemental New Drug Application to FDA Requesting Label Changes for Veltassa Based on Phase 1 Drug-Drug Interaction Studies
May 25, 2016 16:15 ET
|
Relypsa, Inc.
REDWOOD CITY, Calif., May 25, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced that the company has submitted a supplemental New Drug Application...